

Public Register

Public Register

Public Register

*The Genetically Modified Organisms (Contained Use) Regulations (NI) 2015* Contained Use Notification

**Notification of intention to conduct individual contained uses**

 **If the contained use involves working with a biological agent that is listed on schedule 5 of the Anti-terrorism, Crimes and Security Act 2001, this form should not be e-mailed to HSENI because it contains sensitive information. Please print the completed form and send it by post to the Notification Officer, Health & Safety Executive for Northern Ireland, 83 Ladas Drive, Belfast, BT6 9FR. The Schedule 5 list can be found at** [**http://www.legislation.gov.uk/ukpga/2001/24/schedule/5**](http://www.legislation.gov.uk/ukpga/2001/24/schedule/5)

 The public register sections MUST be understandable without reference to the risk assessment or other supporting documents.

 Please return your completed form to the Health and Safety Executive for Northern Ireland at the address given in Notes for Guidance.

 Please do not feel constrained by the box sizes - expand them or continue on separate sheets if necessary.

 Important - please refer to Notes for Guidance where identified.

 Fields marked with an asterisk (\*) must be completed before the form is submitted to HSENI.

FOR HSENI USE ONLY

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GM centre reference: | | | Date notification acknowledged | | | Date contained use ceased | | |
| Dates on which additional information submitted |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| Date on which accident notification submitted | | |  |  |  |  |  |  |

**1. Organisation Details**

\* Name of organisation ***(note 1)***

\* Address

\* Telephone Number Fax Number

E-mail Address

Address(es) of premises where the contained use will actually be conducted (if different from that at Section 1)***(note 1a)***

**2. Date of premises notification *(note 2)***

\* HSENI Centre Number:

GM

**3.  Please check if notifying a connected programme of work *(note 3)***

**4. \* Class(es) of contained use - check all relevant boxes *(note 4)***

Class 2  Class 3  Class 4  Contained use involving notifiable larger GMOs

For class 3 or 4, check box if GMOs are likely to be imported from or exported outside the EC

Contained Use Notification

**5. \* Please give a short descriptive title of the contained use (or contained uses)**

Public Register

Public Register

Public Register

Public Register

Public Register

**6. \* Purpose of the contained use *(note 5)***

**7. \* Characteristics of the GMO(s) including the evaluation of foreseeable effects *(note 6)***

Recipient or parental organism

\* Host / vector system

\* Origins and intended functions of the genetic material involved

Public Register

Public Register

**7. Characteristics of the GMO(s) including the evaluation of foreseeable effects *(cont'd)***

\* Evaluation of foreseeable effects

**8. Containment and control measures for larger GMOs (e.g. GM animals and plants) *(note 7)***

**9. Maximum culture volumes per experiment - for GMMs only *(note 8)***

Public Register

Public Register

Public Register

Public Register

(i) Class 2 contained use, state approximate culture volume

(ii) for class 3 or class 4 contained use, specify the culture volume

**10. For GMMs only, indicate the level of containment that will be applied (please check the appropriate box(es)) *(note 9)***

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Level 2** | **Level 3** | **Level 4** |
| Laboratory contained use |  |  |  |
| Glasshouse |  |  |  |
| Growthrooms |  |  |  |
| Animal Units |  |  |  |
| Large scale contained use (i.e. contained use to which Table 2, Schedule 8 containment is appropriate |  |  |  |
| Human clinical applications |  |  |  |

**11. For GMMs only - application for any derogation from full containment for the class of contained use (measures and justification) *(note 10)***

Public

Register

Public

Register

Public Register

Public Register

**12. \* Describe the waste management measures which you will apply to the contained use (including the type and form, treatment, degree of kill, proposed process testing / monitoring measures, ultimate form and fate) *(note 11)***

**13. \* Is an emergency plan required according to regulation 21?**

Yes  No

If ‘Yes’, please check to confirm that it is attached to this form

**14.  \*Please check to confirm that you have attached a risk assessment to this form (*note 12)***

Please check if you are claiming exemption from disclosure for sections of the risk assessment

**15. \* Please enter comments of the genetic modification safety committee on the risk assessment *(note 13)***

Contained Use Notification

**16. Personal Information**

\* Name of person responsible for supervision and safety of GM contained use at the premises

Training and qualifications

**NON DISCLOSURE OF INFORMATION**

**17. Enter in this section any information required in sections 1-15 which you do not wish disclosed, together with full justification *(note 14)***

**18. Declaration**

**I am notifying an intention to carry out contained use of genetically modified organisms with the authority and approval of the person (organization or individual) named in section 1 of this form**

**Name**

**Position in**

**Signed** (***note 15***) **Date**

**THE GENETICALLY MODIFIED ORGANISMS (CONTAINED USE) REGULATIONS 2014**

**NOTIFICATION OF INTENTION TO CONDUCT INDIVIDUAL CONTAINED USES NOTES FOR GUIDANCE**

**Data Protection Act 1998**

This Act requires the Health and Safety Executive for Northern Ireland (HSENI) to inform you that this form may include information about you (this is called "personal data" in the Act) and that we are a "data controller" for the purposes of the Act. HSENI will process the data for health, safety and environmental purposes. HSENI may disclose these data to any person or organisation for the purposes for which it was collected or where the Act allows disclosure. As data subject, you have the right to ask for a copy of the data and to ask for any inaccurate data to be corrected.

All the information given in sections 1-15 of this form will be placed on HSENI's public register of notifications within 14 days of receipt. You may consider that there is information relevant to these sections whose disclosure would adversely aff ect your organisation's competitive position, intellectual property rights or which you do not wish disclosed on other grounds referred to in the Environmental Information Regulations (EIR) 2004, regulation 12. If so, you should enter such information in section 17 with a full justification for its exemption from disclosure. However, it should always be possible to provide some information in t hese sections for the public register. The Competent Authority will decide whether the information in section 17 will be exempt from disclosure and will notify you of its decision in writing.

Personal information will not be disclosed unless the individual concerned has given his or her explicit written permission.

**Compliance with other legislation**

It is important to note that compliance with the provisions of the Contained Use Regulations does not constitute compliance with other relevant legislation. For example, you may also need to apply separately for licences or permits under legislation con trolling plant health, animal scientific procedures, or the introduction of non-indigenous species. For clinical trials involving gene therapy, you will need ethical approval.

Even if you have fulfilled the requirements of the Contained Use Regulations, and have any necessary consents or approvals under that legislation, you **cannot begin** the contained use unless you also have the relevant licences / permits under any other

applicable legislation.

**Note 1**

This will normally be the University, Institution, Company or Organisation. Only rarely will it be necessary to include an individual's name.

**Note 1a**

If you intend to carry out contained use involving GMMs, you must not leave this section blank unless you are claiming exemption from disclosure. If you are claiming that the precise address of the premises where contained use with larger GMOs (e.g.GM animals or plants) are to be carried out should not be disclosed, you must include this, together with the justification, in section 17.

**Note 2**

**If you have previously notified your premises**, indicate the date of the notification and the HSENI reference number assigned (e.g. GM111). **If you have not notified your premises**, you will not have a reference number so please contact the notification officer (see note 15) or email: [**mail@hseni.gov.uk**](mailto:mail@hseni.gov.uk) for a GM centre reference number. Note that if not previously notified, you will also have to complete a premises application notification - and submit it at the same time as this contained use notification. The fee payable in such cases will only be that related to the contained use notification.

**Note 3**

It is permissible to notify a connected programme of work using this form. However, you must include details of all of the component contained uses in sections 4-15. The fee payable in relation to connected programmes is the fee for the highest class of contained use involved. (notifiable contained use involving larger GMOs are equivalent to class 2 for this purpose).

**Note 4**

Please check all applicable boxes. For class 3 and 4: The EC Regulation 1946/2003 on transboundary movements of Genetically Modified Organisms requires Member States to inform the Biological Clearing House and the European Commission of any decisions on class 3 and class 4 contained use involving GMMs that are likely to be subject to transboundary movements. Transboundary movements are those entering or leaving the European Union. In order for this information to be collected, please check the box if your class is 3 or 4 GMMs are likely to be subject to such transboundary movements. Any information you do not wish disclosed should be entered in section 17 together with the justification.



**Note 5**

Any information you do not wish disclosed should be entered in section 17 together with full justification.

**Note 6**

For contained use involving GMMs, this section **cannot** be left blank unless you have a justified request for non-disclosure in respect of protection of intellectual property rights. If you are not making a request for non-disclosure in respect of intellectual property rights, you must at least include general characteristics of the GMMs involved in the intended contained use. Where there are no justifiable requests for non-disclosure, you must include precise details. An evaluation of the foreseeable effects must also be included, in as precise detail as possible. The evaluation of foreseeable effects should include the identity and characteristics of the GMMs indicated by the risk assessment. Include information on hazards to human health and the environment with particular reference to those arising from the modification as opposed to being inherent properties of the host micro-organism (a fuller

account of these details will be included in the risk assessment).

For contained use involving larger GMOs, it is permissible to request non-disclosure for any of the required information, but the second section should still be completed in as precise detail as possible taking into account it may be disclosed. The evaluation of foreseeable effects is required to consider only human health and safety aspects. Any information you do not wish disclosed should be entered in section 17 together with the justification.

**Note 7**

For contained use involving larger GMOs, describe the containment and control measures which you will apply to the contained use. These should be justified by reference to the risk assessment. Any information you do not wish disclosed should be entered in section 17 together with the justification.

**Note 8**

Any information you do not wish disclosed should be entered in section 17 together with the justification.

**Note 9**

You must not leave this section blank.

**Note 10**

For contained use involving GMMs, you will normally need to apply all the measures specified as requirements for the relevant containment level. If, however, your risk assessment indicates that any of those measures are unnecessary, you may ask for permission to omit them by requesting a derogation(s). Indicate any such measures with a brief justification for the derogation that includes references to the relevant parts of the risk assessment. You **cannot** request non-disclosure for the actual containment measures (unless your intellectual property rights might be affected) BUT you may wish to request exemption for the justification. If a request is made for non-disclosure, the exempt information must be included in section 17 together with the justification.

**Note 11**

Waste management measures which will be applied to the contained use must be described. You should take into consideration only the waste consisting of or containing viable GM material. You must specify the type and form of waste(s) generated, the ir treatment and proposals for testing / monitoring the inactivation process. For contained use involving GMMs, this section cannot be left blank unless you are claiming protection for reasons of intellectual property rights. Even if this is not the case, it is permissible not to give precise details if claims for non-disclosure can be justified. For instance, you could say that inactivation is by heat treatment to give 100% kill, but the precise detail of how this is achieved may be commercially confidential information. If a request is made for non-disclosure, the information must be included in section 17 together with the justification.

**Note 12**

You must attach the risk assessment of the contained use to this form. The risk assessment will not be placed on the public register, but will be open to disclosure to members of the public on request (subject to exemption provisions).

If you wish to claim exemption from disclosure for any sections of the risk assessment, please indicate those sections clearly on the risk assessment and set out a full justification for exemption. If a request for information is received and your justification for non- disclosure is accepted, the risk assessment will be disclosed with the exempt sections removed. You are advised to submit a second version of the risk assessment from which those sections have already been removed. If it is decided, in the public's interest, to release the information, you will be informed of this decision in writing.



**Note 13**

**NB** Remember that, as well as consulting the genetic modification safety committee on the risk assessment, you must also comply with the Safety Representatives and Safety Committees Regulations 1977 and, where any employees are not in groups covered by trade union safety representatives, you must consult such employees according to the Health and Safety (Consultation with Employees) Regulations 1996. If you do not wish some of the information to be disclosed, the exempt information must be

included in section 17 together with the justification.

**Note 14**

Please enter in this section any information, required in sections 1-15, which you wish to be exempt from public disclosure on grounds that:

(a) disclosure would harm your organisation's competitive position; (b) disclosure would compromise your intellectual property rights; or

(c) the information falls into one of the other categories for exemption in the regulation 12 of EIR 2004, state which.

For each piece of information entered you must:

(a) state clearly which grounds applies. In particular, state which category of exemption allowed by the EIR 2004 applies, namely disclosure would adversely affect:

 international relations, defence, national security or public safety

 the course of justice

 confidentiality of proceedings

 commercial / industrial confidentiality

 intellectual property

 protection of the environment

(b) indicate the section of the form to which it is relevant; and

(c) provide a full justification, explaining why the stated ground for exemption applies

**You do not need to enter any personal information as this information is covered by the Data Protection Act and will automatically be treated as confidential.**

**Note 15**

Send the completed form by email to:

[mail@hseni.gov.uk](mailto:mail@hseni.gov.uk)

Or alternatively by post to the address below:

GM Notifications Officer

Health and Safety Executive for Northern Ireland

83 Ladas Drive

Belfast

BT6 9FR

**Note 16**

**If the contained use involves working with a biological agent that is listed on schedule 5 of the Anti-terrorism, Crimes and Security Act 2001, this form should not be e-mailed to HSENI because it contains sensitive information. Please print the completed form and send it by post to the Notification Officer, Health & Safety Executive for Northern Ireland, 83 Ladas Drive, Belfast, BT6 9FR. The Schedule 5 list can be found at** [**http://www.legislation.gov.uk/ukpga/2001/24/schedule/5**](http://www.legislation.gov.uk/ukpga/2001/24/schedule/5)